Benefits and risks during HRT: Main safety issue breast cancer

Hormone Molecular Biology and Clinical Investigation

Volumn 5, Issue 2, 2011, Pages 105-116

  Mueck, Alfred O ^a   Ruan, Xiangyan ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

benefits; breast cancer; hormone replacement therapy (HRT); risks

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COLON CANCER; FRAGILITY FRACTURE; GROUPS BY AGE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VENOUS THROMBOEMBOLISM;

EID: 84858079605     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.014     Document Type: Article

References (91)

1. WHI. Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33.
2. WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-12.
3. Ortmann O. (Leitlinienkoordination). Hormontherapie in der Peri- und Postmenopause. Kurzversion der interdisziplinaren S3-Leitlinie. Frauenarzt 2009;50:840-51.
4. WHI. Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. J Am Med Assoc 2006;295: 1647-57.
5. WHI. Investigators. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357-65.
6. WHI. Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602.
7. WHI. Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
8. Barrett-Connor E., Grady D. Hormone replacement therapy., heart disease., and other considerations. Annu Rev Public Health 1998;19:55-72.
9. Garbe E., Suissa S. Issues to debate on the Women's Health Initiative (WHI) study: hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13.
10. Grodstein F., Manson JE., Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age of hormone initiation. J Women's Health 2006;15:35-44.
11. Moorjani S., Dupont A., Labrie F. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus trans-dermal administration of estrogens. J Clin Endocrinol Metab 1991;73:373-9.
12. Scarabin PY., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post- menopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
13. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid., lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
14. Wakatsuki A., Okatani Y., Ikenoue N., Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771-6.
15. Sumino H., Ichikawa S., Ohyama Y., Takahashi T., Saito Y., Naka-mura T., Kanda T., Kurabayashi M. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005;96:148-53.
16. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., Taskinen MR., Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation., fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25.
17. Decensi A., Omodei U., Robertson C., Bonanni B., Guerrieri-Gonzaga A., Ramazzotto F., Johansson H., Mora S., Sandri MT., Cazzaniga M., Franchi M., Pecorelli S. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106:1224-8.
18. Modena MG., Bursi F., Fantini G., Cagnacci A., Carbonieri A., Fortuna A., Rossi R. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002;113:331-4.
19. Lokkegaard E., Andreasen AH., Jacobsen RK., Nielsen LH., Agger C., Lidegaard O. Hormone therapy and risk of myocar-dial infarction: a national register study. Eur Heart J 2008;29: 2660-8.
20. Renoux C., Dell-Aniello S., Garbe D., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Br Med J 2010;340:c2519.
21. Mueck AO., Seeger H. Cardiovascular risks during HRT in postmenopause. Gynaekol Endokrinol 2007;5:120-6.
22. Miller J., Chan BK., Nelson HD. Postmenopausal replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Service Task Force. Ann Intern Med 2002;136:680-90.
23. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset P. Increased risk of recurrent venous thromboembolism during hormone repacement therapy-results of the randomized., double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84: 961-7.
24. Hoibraaten E., Mowinckel MC., de Ronde H., Bertina RM., Sand-set PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized., double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20.
25. Tans G., van Hylckama Vlieg A., Thomassen MC., Curvers J., Bertina RM., Rosing J., Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-70.
26. Post MS., Christella M., Thomassen LG., van der Mooren MJ., van Baal WM., Rosing J., Kenemans P., Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemo-static variables associated with venous thrombosis: a randomized., placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21.
27. Mueck AO. Editorial: exogenous hormones., the risk of venous thromboembolism (VTE) and activated protein C (APC) resistance. Menopause 2010;17:1099-103.
28. Scarabin PY., Oger E., Plu-Bureau G (for the ESTHER Study Group). Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
29. Canonico M., Fournier A., Carcaillon L., Olie V., Plu-Bureau G., Oger E., Mesrine S., Boutron-Ruault M-C, Clavel-Chapelon F., Scarabin P-Y. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N Cohort Study. Thromb Vasc Biol 2010;30:340-5.
30. Straczek C., Oger E., de Jonage-Canonico MB., Plu-Bureau G., Conard J., Meyer G., Alhenc-Gelas M., Levesque H., Trillot N., Barrellier MT., Wahl D., Emmerich J., Scarabin PY (for the ESTHER Study Group). Prothrombotic mutations., hormone therapy., and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 2005;112:3495-500.
31. Canonico M., Plu-Bureau G., Lowe GD., Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: a systematic review and meta-analy-sis. Br Med J 2008;336:1227-31.
32. Olie V., Plu-Bureau G., Conard J., Horellou M-H, Canonico M., Scarabin P-Y. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:Epub ahead of print.
33. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Levesque H., Trillot N., Barrellier M-T, Wahl D., Emmerich J., Scarbin P-Y. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation 2007;115:840-5.
34. Renoux C., Dell-Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thrombosis Haemostasis 2010;8:979-86.
35. Beral V (Collaborative Group on Hormonal Factors in Breast Cancer). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
36. Shapiro S., Farmer R., Seaman H., Stevenson J., Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1: The Collaborative Reaanalysis. J Family Planning Reprod Health 2011;in press.
37. Seeger H., Mueck AO. HRT and breast cancer caused: caused by progestogens? Experimental vs. clinical data. J Steroid Bio-chem Mol Biol 2008;109:11-5.
38. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;363:419-27.
39. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7.
40. WHI. Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. J Am Med Assoc 2003;289:3243-53.
41. Ragaz J., Wilson K., Muraca G., Budlovsky J., Froehlich J. Endogenous estrogen stimulates exogenous estrogen protects. Further investigation of estrogen chemoprevention is warranted. Presented at the 2010 San Antonio Breast Cancer Symposium., Poster P6-09-09, Abstract No. 1410.
42. J Epidemiol 2008;167:1207-16.
43. J Med 2009;360: 573-87.
44. Lewis-Wambi JS., Craig Jordan V. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 2009;1:206-9.
45. Fournier A., Mesrine S., Boutron-Ruault MC., Clavel-Chapelon F (E3N-Study). Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27: 5116-9.
46. Chen WY., Manson JE., Hankinson SE., Rosner B., Holmes MD., Willett WC., Colditz GA. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166: 1027-32.
47. Opatrny L., DeH'AnieHo S., Assouline S., Suissa S. Hormone replacement therapy and variations in the risk of breast cancer. Br J Obstet Gynecol 2008;115:169-75.
48. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
49. de Lignieres B., de Vathaire F., Fournier S., Urbinelli R., Allaert F., Le MG., Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332-40.
50. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11.
51. Schneider C., Jick SS., Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:514-24.
52. Fournier A., Fabre A., Mesrine S., Boutron-Ruault MC., Berrino F., Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260-8.
53. Krämer E., Seeger H., Krämer B., Wallwiener D., Mueck AO. The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells. Menopause 2005;12:468-74.
54. Neubauer H., Adam G., Fehm T., Seeger H., Neubauer H., Wall-wiener D., Mueck AO. Membrane-initiated effects of progesterone on proliferation and activation of VEGF gene expression in human breast cancer cells. Climacteric 2009;12:230-9.
55. Mueck AO., Seeger H., Shapiro S. Risk of breast cancer during hormone replacement therapy: mechanisms. Horm Mol Biol Clin Invest 2010;3:329-39.
56. Dietel M., Lewis MA., Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052-60.
57. Ellis MJ., Gao F., Dehdashti F., Jeffe DB., Marcom PK., Carey LA., Dickler MN., Silverman P., Fleming GF., Kommareddy A., Jamalabadi-Majidi S., Crowder R., Siegel BA. Lower-dose vs. high-dose oral estradiol therapy on hormone-receptor-positive, aromatase inhibitor-resistant advanced breast cancer. A phase 2 randomized study. J Am Med Assoc 2009;302:774-80.
58. Munster PN., Carpenter JT. Estradiol in breast cancer treatment. Reviving the past. J Am Med Assoc 2009;302:797-8.
59. Seeger H., Wallwiener D., Mueck AO. Influence of stroma-derived growth factors on the estradiol-stimulated proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2004;25: 175-7.
60. Henderson BE., Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
61. Mueck AO., Seeger H. Breast cancer: are oestrogen metabolites carcinogenic. Maturitas 2007;57:42-6.
62. Mueck AO., Seeger H. The World Health Organization defines HRT as carcinogenic-is this plausible? Gynecol Endocrinol 2008;24:129-32.
63. Cogliano V., Grosse Y., Baan R., Straif K., Secretan B., Ghissassi FE (WHO International Agency for Research on Cancer., IARC). Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6:552-3.
64. Schneider HP., Mueck AO., Kuhl H. IARC monographs on car-cinogenicity of combined hormonal contraceptives and meno-pausal therapy (Statement International Menopause Society). Climacteric 2005;8:311-6.
65. Mueck AO., Seeger H. Breast cancer: are estrogen metabolites carcinogenic? Climacteric 2007;10(Suppl 2):62-5.
66. Liehr JG., Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996;93: 3294-6.
67. Chakravarti D., Mailander PC., Higginbotham S. The catechol estrogen-3,4-quinone metabolite induces mutations in the mammary gland of ACI rats. Proc Am Assoc Cancer Res 2003;44:180-6.
68. Rogan EG., Badawi AF., Devanesan PD., Meza JL., Edney JA., West WW., Higginbotham SM., Cavalieri EL. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
69. Seeger H., Deuringer FU., Wallwiener D., Mueck AO. Breast cancer risk during HRT: influence of estradiol metabolites on breast cancer and endothelial cell proliferation. Maturitas 2004;49:235-40.
70. Seeger H., Wallwiener D., Kramer E., Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation., apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72-7.
71. Seeger H., Mueck AO., Lippert TH. Effect of norethisterone acetate on estradiol metabolism in postmenopausal women. Horm Metab Res 2000;32:436-9.
72. Lippert TH., Seeger H., Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the post-menopause. Horm Metab Res 1998;30:598-600.
73. Mueck AO., Seeger H., Wallwiener D. Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas 2002;43:87-93.
74. Dunning AM., Healey CS., Pharoah PD., Teare MD., Ponder AJ., Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:843-54.
75. Bugano DD., Conforti-Froes N., Yamaguchi NH., Baracat EC. Genetic polymorphisms., the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol 2008;29:313-20.
76. Krämer E., Seeger H., Krämer B., Wallwiener D., Mueck AO. Characterization of the stimulatory effect of medroxyprogesterone acetate and chlormadinone acetate on growth factor treated normal human breast epithelial cells. J Steroid Biochem Mol Biol 2006;98:174-8.
77. Krämer E., Seeger H., Kramer B., Wallwiener D., Mueck AO. The effect of progesterone., testosterone and synthetic proges-togens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Reprod Biol 2006; 129:77-83.
78. Neubauer H., Chen R., Schneck H., Knorpp T., Templin MF., Fehm T., Cahill MA., Seeger H., Yu Q., Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Invest 2011;4:in press.
79. Neubauer H., Yang Y., Seeger H., Fehm T., Ruan X., Mueck AO. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011 [accepted].
80. Nielsen M., Jensen J., Andersen J. Precancerous and cancerous breast lesions during Lifetime and at autopsy. Cancer 1984; 54:612-5.
81. Alpers CE., Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16: 796-807.
82. Bartow SA., Pathkak DR., Black WC., Key CR., Teaf SR. Prevalence of benign., atypical and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987;60:2751-60.
83. Black WC., Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43.
84. Schramek D., Leibbrandt A., Sigl S., Kenner L., Pospisilik JA., Lee HJ., Hanada R., Joshi PA., Aliprantis A., Glimcher L. Oste-oclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98-102.
85. Gonzalez-Suarez E., Jacob AP., Jones J., Miller R., Roudier-Mey-er MP., Erwert R., Pinkas J., Branstetter D., Dougall WS. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103-7.
86. Mueck AO., Wallwiener D. Incidence of breast cancer and use of HRT: different data in USA comparing with Europe. Fraue-narzt 2007;48:812-6.
87. Pelucchi C., Levi F., La Vecchia C. The rise and fall in meno-pausal hormone therapy and breast cancer incidence. Breast 2010;19:198-201.
88. De P., Neutel CI., Olivotto I., Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 2010;102:1489-95.
89. Kenemans P., Bundred NJ., Foidart JM., Kubista E., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Yip CJ., Mol-Arts M., Mulder R., van Os S., Beckmann MW (LIBERATE Study Group). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized., non-inferiority trial. Lancet Oncol 2009;10:135-46.
90. Kenemans P., Beckmann MW., Bundred J., Foidart JM., Kubista E., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Yip CH., Egberts J., Gomez JP., Mulder R., van Os S. Tibolone in breast cancer patients: first results of the LIBERATE trial. Climacteric 2008;11(Suppl 2):25-6.
91. Kenemans P., Beckmann MW., Bundred J., Foidart JM., Kubista E., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Yip CH., Egberts J., Gomez JP., Mulder R., van Os S; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Eng J Med 2008;359:697-708.